Regenexbio and Neurimmune AG have entered an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.
 
“Regenexbio is at the forefront of research and development of AAV-mediated antibody gene therapies,” said Olivier Danos, chief scientific officer, Regenexbio. “We are thrilled to initiate our partnership with Neurimmune, which builds on promising results to date with our RGX-314 clinical-stage program, where we are using our NAV Vectors to deliver a therapeutic antibody for the treatment of wet AMD.” 
 
“Neurimmune’s Reverse Translational Medicine technology decodes the genetic information of immune cells obtained from healthy aged people to identify next generation antibody therapeutics,” said Jan Grimm, chief scientific officer, Neurimmune. “We are excited to partner with Regenexbio and combine our human antibody technology with Regenexbio’s AAV expertise to develop vectorized human antibodies as a novel treatment modality. We believe the potential to deliver sustained levels of therapeutic human antibodies to the brain with AAV vectors may have a significant impact on chronic neurodegenerative conditions.”